Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patie...
November 16 2020 - 11:12AM
Telo Genomics Corp. (TSX-V: TELO) (the
“Company” or
“TELO”) is pleased
to announce the positive results of its smoldering multiple myeloma
proof of concept study, recently published within the proceedings
of the American Society of Hematology (ASH) annual meeting 2020.
In this published study, TeloView®’s
quantitative and spatial analysis of 6 key parameters of telomeres
was conducted on a total of 26 patients that were diagnosed with
smoldering multiple myeloma. The cohort included 21 stable patients
who remained at the smoldering stage for over 5 years and 5
high-risk patients that progressed to the active multiple myeloma
stage within 2 years from point of diagnosis. A high level of
statistical significance was observed across all of the 6
parameters measured by TeloView®, and the analysis distinguished
between the group of patients that remained stable with smoldering
multiple myeloma from the group that progressed to active multiple
myeloma in 26 out of the 26 patients-cohort.
The study was conducted blindly on the
diagnostic specimens suggesting the capability of TeloView®
analysis to stratify smoldering multiple myeloma patients at the
point of diagnosis. These results have the potential to guide
evidence-based decisions to treat smoldering multiple myeloma
patients with a high risk of progression, addressing a critical
unmet clinical need in the management of multiple myeloma.
Telo Genomics is conducting further studies on expanded cohorts
of patients to further validate the results obtained from this
proof of concept study, and to confirm the utility of its TeloView®
technology to predict the progression of smoldering multiple
myeloma in patients.
The full text of the abstract is available at the November 2020
supplemental issue of the scientific journal “Blood” –
https://ashpublications.org/blood/article/136/Supplement%201/19/473649/Three-Dimensional-Telomere-Analysis-Using?searchresult=1
Multiple myeloma is a highly challenging and
deadly blood cancer that forms in plasma cells, a type of white
blood cell. Symptoms include bone pain, frequent infections,
fatigue, and weight loss. Smoldering multiple myeloma is an
asymptomatic precursor to active multiple myeloma. There is an
increasing industry trend towards identifying high-risk smoldering
multiple myeloma patients to initiate early treatment and achieve
better clinical outcomes (Boutros M. et al 2020). The annual
incidence of multiple myeloma is approximately 32,000 newly
diagnosed cases in the USA per year, with approximately 250,000
cases of smoldering multiple myeloma, of which 10-15% of smoldering
multiple myeloma patients progress to active multiple myeloma every
year.
“These published results are encouraging for
TeloView® and indicates that it has the potential to fill an
important unmet diagnostic/prognostic need for smoldering multiple
myeloma,” said Guido Baechler, TELO’s Chairman, “We look forward to
further validation in our additional clinical studies, and we see
now the potential for establishing future strategic partnerships to
accelerate the transition of TeloView® tests towards
commercialization.”
Reference: Boutros M. et al
Genomic Profiling of Smouldering Multiple Myeloma Identifies
Patients at a High Risk of Disease Progression. J Clin Oncol. 2020
Jul 20;38(21):2380-2389
The American Society of Haematology
represents healthcare professionals involved in the management of
blood disorders including cancer. The ASH annual meeting is one of
the top clinical international meetings focused on blood cancers.
ASH attracts more than 30,000 attendees, predominantly
clinicians.
About Telo Genomics
Telo Genomics is a biotech company pioneering
the most comprehensive telomere platform in the industry with
powerful applications and prognostic solutions. These include
liquid biopsies and related technologies in oncology and
neurological diseases. Liquid biopsy is a rapidly growing field of
significant interest to the medical community for being less
invasive and more easily replicated than traditional diagnostic
approaches. By combining our team’s considerable expertise in
quantitative analysis of 3D telomeres with molecular biology and
artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate
products that improve day-to-day care for patients by serving the
needs of pathologists, clinicians, academic researchers and drug
developers. The benefits of our proprietary technology have been
substantiated in over 150 peer reviewed publications and in 25
clinical studies involving more than 3,000 patients with multiple
cancers and Alzheimer’s disease. Our lead application, Telo-MM is
being developed to provide important, actionable information to
medical professionals in the treatment of Multiple Myeloma, a
deadly form of blood cancer. For more information please visit
www.telodx.com.
For further information, please
contact:
Hugh Rogers,
Director416-673-8487info@telodx.comMaRS Centre, South Tower, 101
College Street, Suite 200, Toronto, ON, M5G 1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements
Certain information contained herein may constitute
“forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“intends”, “will”, or variations of such words and phrases or
statements that certain actions, events or results “will” occur.
Forward-looking statements regarding the clinical efficacy of
products, commercial viability of products, use of proceeds, and
the ability of the TeloViewTM platform to deliver personalized
medicine resulting in better treatments and outcomes are based on
the Company’s estimates and are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information,
including capital expenditures and other costs. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. The Company will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
Telo Genomics (TSXV:TELO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Telo Genomics (TSXV:TELO)
Historical Stock Chart
From Dec 2023 to Dec 2024